International Journal of Public Health and Preventive Medicine, 2020, 1(3); doi: 10.38007/IJPHPM.2020.010301.
China Pharmaceutical University, Nanjing, China
With the increasing morbidity and mortality of patients with multiple myeloma (MM), new immunomodulatory agents, new-generation proteasome inhibitors, monoclonal antibodies and other new drugs have been introduced, but the therapeutic effects are not obvious. Ixazosamine, lenalidomide and dexamethasone are among the drugs for the treatment of MM patients. In order to find a more effective method for the treatment of MM, this article collected 21 patients with relapsed and refractory MM who received oxazide combined with lenalidomide and dexamethasone regimen from June 2014 to April 2018 in the Department of Hematology, Jinhua People's Hospital, Zhejiang Province. MM patients were treated with oxazolamide, lenalidomide and dexamethasone. In the MM patients in the study, 7 patients in the thalidomide exposure group and 6 patients in the unexposed group, the response rates of the two groups were 71% (5/7) and 67% (4/6), respectively. For thalidomide-resistant patients, the combination group still showed higher ORR and longer TTP and PFS than the dexamethasone monotherapy group. Lenalidomide combined with dexamethasone was effective in patients with relapsed and refractory MM with mild adverse reactions. This article also analyzed the efficacy of 61 patients with light chain, 153 patients with IgG and 39 patients with IgA MM who underwent autologous stem cell transplantation. The results showed that the median OS of patients with light chain MM was 2.8 years and the EFS was 1.2 years. Shorter than IgG-type MM patients (4.5 years, P = 0.03 and 2.1 years, P = 0.03).
Multiple Myeloma, Thalidomide and Dexamethasone and Lenalidomide, Light Chain
Xianhua Qiao. Effectiveness of Isazomil Combined with Lenadomide and Dexamethasone in the Treatment of Recurrent and Refractory Multiple Bone Marrow. International Journal of Public Health and Preventive Medicine (2020), Vol. 1, Issue 3: 1-12. https://doi.org/10.38007/IJPHPM.2020.010301.
 Group, T. S. (2016) “Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.” New England Journal of Medicine, 374(17), pp. 1621.
 Dimopoulos, M. A., Oriol, A., Nahi, H., Sanmiguel, J., Bahlis, N. J., & Usmani, S. Z., et al. (2016) “Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma — NEJM.” New England Journal of Medicine, 375(14), pp. 1319. https://doi.org/10.1056/NEJMoa1607751
 Angelo, V., Roberto, R., Fabrizio, S., Francesca, M., Mauro, C., & Angela, B., et al. (2016) “Endothelial Cells in the Bone Marrow of Patients with Multiple Myeloma.” Blood, 102(9), pp. 3340. https://doi.org/10.1182/blood-2003-04-1338
 Bertolini, F., Mingrone, W., Alietti, A., Ferrucci, P. F., Cocorocchio, E., & Peccatori, F., et al. (2016) “Thalidomide in Multiple Myeloma, Myelodysplastic Syndromes and Histiocytosis. Analysis of Clinical Results and of Surrogate Angiogenesis Markers.” Annals of Oncology, 12(7), pp. 987-990. https://doi.org/10.1023/A:1011141009812
 Berenson, J. R., Crowley, J. J., Grogan, T. M., Zangmeister, J., & Salmon, S. E. (2016) “Maintenance Therapy with Alternate-Day Prednisone Improves Survival in Multiple Myeloma Patients.” Blood, 99(9), pp. 3163-3168. https://doi.org/10.1182/blood.V99.9.3163
 Dimopoulos, M. A., & Al, E. (2016) “Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma (Endeavor): A Randomised, Phase 3, Open-Label, Multicentre Study.” Lancet Oncology, 17(1), pp. 27-38.
 Kobayashi, T., Miura, M., Abumiya, M., Niioka, T., Kanno, S., & Takahashi, N. (2018) “The Potential Role of Clarithromycin Addition to Lenalidomide and Dexamethasone Therapy (Bird) in Multiple Myeloma.” Annals of Hematology, 97(11), pp. 1-3. https://doi.org/10.1007/s00277-018-3270-4
 Díaz, T., Rodríguez, Vanina, Lozano, Ester, Mena, Mari-Pau, Calderón, Marcos, & Rosi?ol, Laura, et al. (2017) “The Bet Bromodomain Inhibitor CPI203 Improves Lenalidomide and Dexamethasone Activity in Vitro and in Vivo Models of Multiple Myeloma by Blockade of Ikaros and MYC Signaling.” Haematologica, 102(10), pp. 1776. https://doi.org/10.3324/haematol.2017.164632
 Anderson, & K., C. (2016) “Progress and Paradigms in Multiple Myeloma.” Clinical Cancer Research, 22(22), pp. 5419-5427. https://doi.org/10.1158/1078-0432.CCR-16-0625
 Iida, S., Nagai, H., Kinoshita, G., Miyoshi, M., Robbins, M., & Pandya, D., et al. (2017) “Elotuzumab with Lenalidomide and Dexamethasone for Japanese Patients with Relapsed/Refractory Multiple Myeloma: Phase 1 Study.” International Journal of Hematology, 105(3), pp. 326-334. https://doi.org/10.1007/s12185-016-2138-4
 Nakamura, D., Hayashida, M., Kubota, K., Matsuura, E., Tabuchi, T., & Arima, N., et al. (2018) “[Successful Treatment of Poems Syndrome-Associated Pulmonary Hypertension with Lenalidomide and Dexamethasone Therapy].” The Japanese journal of clinical hematology, 59(5), pp. 489.
 Uchida, T., Inoue, M., Hua, J., & Hagihara, M. (2016) “Achievement of Hemodialysis Discontinuation with Lenalidomide and Dexamethasone Therapy in A Refractory BJP-type Multiple Myeloma Patient.” Rinsho Ketsueki, 57(5), pp. 613-617.